Relmada Therapeutics, Inc. (RLMD) Q2 FY26 Earnings Call

$217.7 million cash funds operations through 2029, including NDV01 Phase 3 completion. [15]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length31 minutes
EPS$-0.11
EPS consensus$-0.21
Revenue$959762.00

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q4 FY25 · Q3 FY25 · Q2 FY25

All RLMD earnings · Back to RLMD overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.